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Abstract
 
Experiments were performed to characterize and identify the cellular sources of the secondary in-
terleukin (IL)-4 response to a T cell–dependent antigen. Mice were primed by immunization
with goat anti–mouse immunoglobulin (Ig)D antibody (GaMD), which stimulates naive CD4
 
 
 
T cells to secrete IL-4 in 3–4 d. When challenged with goat serum 14 d after immunization,
GaMD-primed mice generated an IL-4 response that exceeded the primary response by 
 
 
 
100-
fold, started in 
 
 
 
2 h, and lasted for 4 d. Studies with 4get mice, in which cells with an accessible
 
Il4
 
 gene express a green fluorescent protein (GFP), revealed CD4
 
 
 
 memory T cells, natural killer
T cells, basophils, mast cells, and eosinophils as possible rapid producers of IL-4. GFP
 
 
 
CD4
 
 
 
 T
cells and basophils expanded more in the spleen than the other cell types during the primary re-
sponse to GaMD. Quantitation of in vivo IL-4 production by the in vivo cytokine capture assay
after individual cell types were selectively stimulated or deleted demonstrated that basophils and
memory CD4
 
 
 
 T cells account for most of the secondary IL-4 response, with basophils initiating
that response through IgE/Fc
 
 
 
RI-mediated signaling but secreting IL-4 for 
 
 
 
4 h and memory T
cells secreting IL-4 within 4 h and continuing to secrete this cytokine for 4 d.
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Introduction
 
IL-4 both protects hosts against intestinal worm infections
(1) and contributes to the pathogenesis of allergy (2). Sev-
eral cell types have been reported to produce IL-4, includ-
ing conventional CD4
 
 
 
 and CD8
 
 
 
 T cells (3, 4), NKT
cells (5), basophils (6), mast cells (7) and eosinophils (8).
CD4
 
 
 
 T cells appear to be critical for the generation of a
primary IL-4 response: the large IL-4 responses produced
in mice treated with the potent TD antigen goat anti–
mouse IgD antibody (GaMD) or in mice infected with the
intestinal nematode parasite 
 
Nippostrongylus brasiliensis
 
 are
almost totally blocked if these mice are depleted of CD4
 
 
 
T cells by treating them with anti-CD4 mAb (9, 10). In
contrast with the CD4
 
 
 
 T cell dependence of a primary
IL-4 response, little is known about the relative contribu-
tions of different cells types to the production of IL-4 dur-
ing a secondary immune response or chronic immune
stimulation. Identification of the cellular sources of IL-4 in
the secondary response is important because the chronic
nature of most allergic disorders suggests that patterns of
IL-4 production in patients with these disorders will resem-
ble those generated during a secondary, rather than a pri-
mary, response. Indeed, studies of nasal and bronchial cells
from patients with allergic rhinitis and atopic asthma have
identified IL-4–producing basophils, mast cells, and eosino-
phils, as well as T cells (8, 11), and some of these studies
suggest that most IL-4 is produced by the non–T cells.
The importance of non–T cells as sources of IL-4 pro-
duction is also suggested by studies performed with two
strains of transgenic mice: G4 mice, in which the first exon
and a portion of the first intron of the 
 
Il4
 
 gene have been
replaced by the 
 
Gfp
 
 gene that encodes enhanced GFP (12)
and C.129-IL4
 
tmILK4
 
 mice (4get mice) in which the 
 
Il4
 
gene was modified by the 3
 
 
 
 addition of an internal riboso-
mal entry sequence (4get mice; reference 13). Studies with
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G4 mice now demonstrate that IL-4 is produced by T cells
and basophils after intestinal worm infection (14), whereas
studies with 4get mice have additionally suggested that
eosinophils may be important IL-4–producing cells (15).
Complicating the interpretation of these studies has been a
concern that both stability and regulation of translation
may differ for GFP mRNA versus IL-4 mRNA in both
mouse strains and that internal ribosomal entry sequence–
regulated mRNA and protein expression in 4get mice may
correlate more with 
 
Il4
 
 gene accessibility than with actual
 
Il4
 
 gene transcription and translation (16, 17). As a result,
the relative roles of T cells, basophils, mast cells, and eo-
sinophils as sources of IL-4 during a chronic or secondary
Th2 response remain controversial.
To better understand this issue, we have studied a system
in which initial immunization of mice with GaMD induces
a strong, CD4
 
 
 
 T cell–dependent IgG1 and IgE antibody
response that is accompanied by an 
 
 
 
100-fold increase in
CD4
 
 
 
 T cell 
 
Il4
 
 gene expression and protein secretion (18,
19). Although antibody and IL-4 production generally re-
turn to near baseline levels by 2 wk after the initial GaMD
immunization, we find that challenge of previously immu-
nized mice with goat serum induces a dramatic, rapid IL-4
response that can last for several days. We now characterize
this response further by studying the effect of primary
GaMD immunization on GFP expression in 4get mice; by
evaluating the importance of mast cells, eosinophils, baso-
phils, conventional CD4
 
 
 
 T cells, NKT cells, IgE, and
Fc
 
 
 
RI in the secondary IL-4 response; and by comparing
the IL-4 response generated by challenging goat IgG-immune
mice with normal goat serum to that induced by challeng-
ing these mice with an anti-IgE mAb.
 
Materials and Methods
 
Mice. 
 
BALB/c mice were purchased from the National Can-
cer Institute. Mast cell–deficient WBB6F1-
 
Kit
 
W
 
/Kit
 
W-v
 
 (W/W
 
v
 
)
mice, (WBB6F1-
 
Kit
 
W
 
/Kit
 
W-v
 
 
 
 
 
 WBB6F1-
 
   
 
)F1 (W/
 
 
 
) mice
(which have a normal phenotype), and 4get mice were purchased
from The Jackson Laboratory. CD1/CD2-deficient and CD1/
CD2
 
   
 
 mice were a gift from A. Bendelac (University of Chi-
cago, Chicago, IL), who produced them by backcrossing the orig-
inal C57BL/6 
 
 
 
 129 CD1/CD2-deficient mice (20) to BALB/c
mice for 12 generations (21). Fc
 
 
 
RI
 
 
 
-deficient mice (22) were a
gift from J.-P. Kinet and IgE-deficient mice (23) were a gift from
P. Leder (both of Harvard University, Boston, MA).
 
Reagents. 
 
The following antisera, antibodies, and mAbs were
prepared as described: goat antisera to mouse IgD (GaMD) and
keyhole limpet hemocyanin (GaKLH; reference 24); H
 
 
 
a
 
/1
(mouse IgG2b anti–mouse IgD
 
a
 
; reference 25); FF1-4D5 (mouse
IgG2a anti-IgD
 
a
 
; reference 26); GK1.5 (rat IgG2b anti–mouse
CD4; reference 27); 2.43 (rat IgG2b anti-CD8; reference 28);
J1.2, GL113, and GL117 (rat IgG2b anti-NP, rat IgG1, and
IgG2a anti–
 
Escherichia coli
 
 
 
 
 
-galactosidase, used as controls; a gift
from J. Abrams, DNAX, Palo Alto, CA); EM-95 (rat IgG2a anti–
mouse IgE; reference 29); 24G2 (rat IgG2b anti–mouse Fc
 
 
 
RII/
RIII; reference 30); IgEL2a (mouse IgE anti-TNP; reference 31);
RB6-8C5 (rat IgG2b anti-Ly6G/C; reference 32); and 145-2C11
(Armenian hamster IgG1 anti-CD3; reference 33). The following
mAbs to mouse cytokines were obtained from BD Biosciences
(the original references for each of these mAbs are available in the
BD Biosciences catalogue): biotin-JES6-5H4 (rat IgG2b anti–IL-2),
JES6-1A12 (rat IgG2a anti–IL-2), biotin-MP2-8F8 (rat IgG1
anti–IL-3), MP2-43D11 (rat IgG2a anti–IL-3), biotin-BVD4-
1D11 (rat IgG2b anti–mouse IL-4), BVD6-24G2.3 (rat IgG1
anti–IL-4), biotin-TRFK-4 (rat IgG2a anti–IL-5), JES1-39D10
(rat IgG2a anti–human/mouse IL-5), biotin-R46A2 (rat IgG1
anti–IFN-
 
 
 
), AN-18 (rat IgG1 anti–IFN-
 
 
 
), biotin-TN3 (Arme-
nian hamster IgG1 anti-TNF), G281-2626 (rat IgG1 anti-TNF),
DX5 (rat IgM anti–mouse Ly49b), GL3 (Armenian hamster IgG2
anti-TCR
 
 
 
), and H57-597 (Armenian hamster IgG2 anti-
TCR
 
 
 
). The mAb 83101 (rat IgG2a anti-CCR3) and affinity
purified goat anti–mouse IL-13 were purchased from R&D Sys-
tems. 11B11 (rat IgG1 anti–mouse IL-4; reference 34) was pur-
chased from Verax. C531 (rat IgG anti–mouse IL-13) was a gift
from S. Visvanathan (Centocor, Malvern, PA). CD1/
 
 
 
-galacto-
sylceramide (
 
 
 
-gal-cer) tetramers were a gift from A. Bendelac
and were prepared and used to identify NKT cells as described
previously (35). Recombinant murine IL-3, IL-4, and IL-9 were
purchased from PeproTech.
 
Administration of Cytokines. 
 
IL-3 and IL-4 were administered
as complexes with the neutralizing mAbs MP2-8F8 and 11B11,
respectively. These complexes (IL-3C and IL-4C), which are
prepared by mixing the cytokine and anticytokine mAb at a 2:1
molar ratio, slowly dissociating in vivo, and releasing the free cy-
tokine. A single injection of IL-4C or IL-3C maintains activity of
the relevant cytokine for 
 
 
 
3 d. These complexes do not fix C,
bind more avidly than free IgG to Fc
 
 
 
Rs, or interact simulta-
neously with Fc
 
 
 
Rs and cytokine receptors (36).
 
Measurement of Mouse Mast Cell Protease 1 (MMCP1). 
 
Se-
rum levels of MMCP1, an indicator of mucosal mast cell degran-
ulation (37), were measured with a kit purchased from Moredun
according to the manufacturer’s directions.
 
Immunofluorescence Staining and Flow Cytometry. 
 
Four-color
flow cytometry was performed with a BD FACScalibur equipped
with argon and red diode lasers (BD Biosciences). Fluorescein,
GFP, or Alexafluor 488; phycoerythrin; PerCP; and allophycocy-
anin, Cy5, or Alexafluor 647 were used as the four fluorochromes.
Cells stained with anti-IgE mAb were pretreated with IgE mAb in
vitro in the presence of anti-Fc
 
 
 
RII mAb to load Fc
 
 
 
RI. Data
were analyzed with CELLQuest software (BD Biosciences).
 
In Vivo Cytokine Capture Assay (IVCCA). 
 
In vivo cytokine
production was analyzed with the IVCCA, which increases the
sensitivity of cytokine detection 
 
 
 
100-fold (19, 38). Mice are in-
jected with 10 
 
 
 
g of biotin-labeled, neutralizing anticytokine
mAb, which binds secreted cytokine. Cytokine-biotin–anti-cyto-
kine mAb complexes accumulate to much higher levels than free
cytokines in serum and are measured by ELISA, using microtiter
plate wells coated with mAb to a second, noncompeting epitope
on the cytokine molecule to capture the complex and a horseradish
peroxidase–streptavidin conjugate (Pierce Chemical Co.) and a lu-
minogenic substrate for horseradish peroxidase (SuperSignal
 
 
 
ELISA
femto-substrate; Pierce Chemical Co.) to detect the captured com-
plex. Luminescence is measured with a Fluoroskan Ascent FL mi-
crotiter plate luminometer/fluorometer (Labsystems).
 
Immunization and Challenge. 
 
Mice were primed in most ex-
periments by injecting them i.p. with 0.2 ml of GaMD. Goat IgG
in GaMD binds to B cell membrane IgD and activates these cells.
It is also internalized, processed, and presented to goat IgG-spe-
cific T cells. The huge number of goat IgG-presenting activated
B cells acts as a potent stimulus for the activation of goat IgG-spe-
cific CD4
 
 
 
 T cells and induces a substantial effector T cell re-
sponse that is characterized by predominantly Th2 cytokine se- 
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cretion and later, a substantial memory T cell response. GaKLH
does not directly activate B cells or indirectly induce a large pri-
mary T cell response; however, it contains the same antigenic de-
terminants as GaMD. This allows GaKLH to be used as the chal-
lenge antigen for GaMD-primed mice.
 
Online Supplemental Material. 
 
Fig. S1 illustrates the gating
strategy used to define: GFP
 
 
 
CD4
 
 
 
 T cells (gates R1–R3), eo-
sinophils (gates R4 and R5), and basophils (gates R4 and R6).
Online supplemental material is available at http://www.jem.
org/cgi/content/full/jem.20040598/DC1.
 
Results
 
Comparison of Primary and Secondary IL-4 Responses to
GaMD. 
 
Activation of CD4
 
 
 
 T cells during the primary
response to GaMD induced IL-4 production (Fig. 1 A) that
peaked 5–7 d after immunization (27–29). To determine
whether GaMD immunization primes for a memory IL-4
response, GaMD-primed mice were challenged 14 d after
priming with GaKLH and IL-4 production was followed
by IVCCA. An IL-4 response developed 
 
 
 
2 h after chal-
lenge and peaked, at a level 50–100-fold greater than the
primary response, at 4–6 h. IL-4 production subsequently
decreased but remained elevated for 4–5 d (Fig. 1 B and
not depicted). Thus, mice immunized with a TD antigen
can rapidly produce IL-4 during a secondary response.
 
Identification of Cells That Have an Accessible Il4 Gene in
GaMD-immunized Mice. 
 
Studies were performed with
GaMD-immunized 4get mice to identify cell types that
might be able to rapidly produce IL-4 in response to anti-
gen challenge. GFP in 4get mice is not expressed by naive,
conventional CD4
 
 
 
 T cells, but is constitutively expressed
by most basophils, eosinophils, and NKT cells (14, 15, 39),
suggesting that the 
 
Il4
 
 gene is constitutively accessible in
these latter cell types. Most GFP
 
 
 
 cells in unstimulated 4get
mice must secrete little or no IL-4 because IL-4 levels are
low in these mice, as measured by the IVCCA (unpub-
lished data); however, the open configuration of the 
 
Il4
 
gene in these cells implies that they can rapidly secrete IL-4
when appropriately activated.
With this in mind, we evaluated the effects of primary
GaMD immunization of 4get mice on splenic GFP
 
 
 
 cell
populations. These studies (Figs. 2 and 3 and Fig. S1,
available at http://www.jem.org/cgi/content/full/jem.
20040598/DC1) demonstrated a large increase in the num-
ber of GFP
 
 
 
CD4
 
 
 
TCR
 
 
 
 
 
TCR
 
 
 
 
 
 T cells, which peaked
5–8 d after GaMD immunization (Figs. 2 A and 3, A and
B). Although 80–90% of GFP
 
 
 
 T cells in unimmunized
4get mice can be identified as NKT cells by virtue of their
binding of CD1/
 
 
 
-gal-cer tetramers and most NKT cells
are GFP
 
 
 
 even in unimmunized mice (Figs. 2 A and 3 A
and reference 39), and although both conventional (CD1/
 
 
 
-gal-cer tetramer nonbinding) and NKT cells become ac-
tivated during the response to GaMD as reflected by in-
creased forward light scatter (Fig. 3 A), only the conven-
tional CD4
 
 
 
GFP
 
 
 
 T cell population increases in number
during this response (Fig. 3 A). Conventional GFP
 
 
 
CD4
 
 
 
T cell number is still increased several-fold over baseline
14 d after GaMD immunization, but forward light scatter
by these cells has returned to baseline (Fig. 3, A and C),
suggesting that they have memory, rather than effector,
function at this time. This supposition is consistent with
evidence, shown below, that IL-4 production has returned
to baseline by 14 d after GaMD immunization in most
experiments.
Two splenic cell types, in addition to CD4
 
 
 
 T cells, ex-
press GFP in GaMD-immunized 4get mice. One cell type
can be identified as eosinophils (SSC
 
high
 
CCR3
 
high
 
Ly6G/
C
 
 
 
c-kit
 
low
 
Ly49b
 
 
 
IgE
 
 
 
) (13, 40); the other can be identi-
fied as basophils (SSC
 
intermediate
 
Ly49b
 
high
 
CCR3
 
low
 
IgE
 
 
 
c-kit
 
 
 
CD4
 
 
 
Ly6G/C
 
 
 
) (Fig. 2 B; reference 14; unpublished
data). In contrast, GaMD immunization does not elicit de-
monstrable numbers of GFP
 
  cells with a CD4 c-kit IgE 
mast cell phenotype. Nearly all eosinophils and basophils in
4get mice are GFP  before immunization (Fig. 3 D). Both
Figure 1. Comparison of primary and secondary responses to GaMD.
(A) BALB/c mice (5/group in this and other experiments unless other-
wise indicated) were left untreated or were immunized i.p. with GaMD.
All mice were injected i.v. with 10  g biotin-BVD4-1D11 anti–IL-4
mAb (B IL-4) and were bled 1 d later at the time points shown for
GaMD-immunized mice. Serum IL-4 levels were determined by
IVCCA. Geometric means and SE are shown in this and in subsequent
figures. (B) BALB/c mice were immunized with GaMD and challenged
with 0.2 ml GaKLH 14 d later. Challenged mice were also injected with
BaIL-4 0, 4, 8, 20, 48, 72, or 96 h later and were bled 2 h after that, at the
time points shown. Thus, the first point shows IL-4 produced between 0
and 2 h after challenge. IL-4 levels were not determined in this experi-
ment before challenge on day 14, but have been  200 pg/ml in several
other experiments.Secondary IL-4 Response 860
basophils and eosinophils increase in percentage and abso-
lute number in the spleen after GaMD immunization (Fig.
3, E and F), but basophils increase considerably more than
eosinophils and basophils, but not eosinophils, exhibit an
increase in the amount of GFP expressed per cell (Fig. 3, F
and G).
Effects of IL-3, IL-4, and IL-9 on GFP-expressing Cells in
4get Mice.  Because GaMD immunization stimulates the
production of IL-3, IL-4, and IL-9 (but not IL-5; reference
18) and each of these cytokines can activate basophils, mast
cells, T cells, and/or eosinophils (41), we evaluated the ef-
fects of in vivo treatment of 4get mice with each cytokine
Figure 2. Changes in GFP-
expressing spleen cells during the
primary response to GaMD in
4get mice. 4get and wild-type
mice (4/group) were injected
with saline or GaMD and killed
1–14 d later. Spleen cells were
stained with combinations of flu-
orochrome-labeled mAbs to
CD3, CD4, CD8, IgE, Ly49b,
TCR , TCR , c-kit, CCR3,
and Ly6G/C and with CD1/
 -gal-cer tetramers. Stained cells
were analyzed by four-color,
dual laser flow cytometry. Histo-
grams show staining with a spe-
cific mAb as a fine line; staining
with a control mAb or no mAb
as a bold line. Gating strategies
are shown in Fig. S1. (A)
CD4 CD8  spleen cells were
analyzed for GFP expression,
and GFP CD4  cells were ana-
lyzed for expression of TCR 
and TCR  and staining with
CD1/ -gal-cer tetramers. The
text within the panels indicates
gating and time after GaMD
immunization. (B) GFP CD3 
spleen cells were analyzed for
FSC and side scatter (SSC) of in-
cident light. GFP CD3  spleen
cells with moderate or high SSC
were analyzed for expression of
surface marker expression. The
text within the panels shows
normalized median fluorescence
intensity of staining (NMFI), de-
fined as (median fluorescence in-
tensity of specifically stained
cells)   (median fluorescence in-
tensity of cells not stained with
the relevant mAb).Khodoun et al. 861
on GFP  spleen cells and additionally compared GFP 
spleen cell populations in 4get versus 4get mice that also
expressed an IL-5 transgene (Fig. 4). IL-3, IL-4, and IL-9
each induced a two- to threefold increase in the number of
splenic basophils, and IL-3 and IL-9, but not IL-4, stimu-
lated a substantial increase in splenic eosinophil number
(Fig. 4 B). Transgenic overproduction of IL-5 induced
massive splenic eosinophilia, but had no significant effect
on basophils (Fig. 4 B).
Only IL-3 elicited substantial numbers of GFP IgE 
c-kit  spleen cells, which are most likely mast cells. These
cells expressed more GFP/cell than the IgE c-kit  basophils
(Fig. 4 C) and scattered light somewhat more than the
IgE c-kit  basophils (not depicted). No cytokine tested in-
Figure 3. Characterization of
GFP  spleen cells during the pri-
mary response to GaMD. Data
obtained from the experiments
described in Fig. 2 were used to
calculate the following. (A)
Numbers of GFP  splenic con-
ventional CD4  T cells and
NKT cells (left), percentages of
splenic conventional CD4  and
NKT cells that expressed GFP
(middle), and median forward
scatter of splenic conventional
CD4  T cells and NKT cells
(right). (B) Percentages of CD4 
and CD8  T cells that expressed
GFP. (C) Median FSC of
CD4 GFP  and CD4 GFP 
spleen cells. (D) Percentages of
splenic basophils and eosinophils
that expressed GFP. (E) Total
spleen cell number. (F) Percent-
ages of splenic basophils, eosino-
phils, CD8  T cells, and CD4 
T cells. (G) Median GFP fluores-
cence intensity of basophils, eo-
sinophils, and GFP CD4  T
cells.Secondary IL-4 Response 862
creased CD4  T cell GFP expression (unpublished data).
Thus, although increased cytokine production may account
for some of the increase in splenic basophils and eosinophils
in GaMD-immunized mice, other effects of GaMD immu-
nization must account for the increase in GFP CD4  T
cells and most of the increase in splenic basophils.
Basophils and Conventional CD4  T Cells Are the Main
Sources of IL-4 in the Secondary Response to Goat Serum.
The studies depicted in Figs. 2–4 implicate CD4  T cells,
eosinophils, basophils, and, possibly, nonsplenic mast cells as
possible sources of the rapid IL-4 response to goat serum
challenge in GaMD-primed mice. In vivo studies (Figs. 5–7)
Figure 4. Cytokine effects on spleen cell number and GFP
expression in 4get mice. In three separate experiments, 4get
mice (4/group) were injected i.v. with saline, IL-3C (10  g of
IL-3   50  g of anti–IL-3 mAb on days 0, 3, and 6), or IL-4C
(2  g IL-4   10  g anti–IL-4 mAb on days 0, 3, and 6), or
i.p. with IL-9 (10  g/d for 7 d). Mice were killed on day 8,
and spleen cells from individual mice were counted with a
Coulter Counter and stained with fluorochrome-labeled mAbs
to CD3, IgE, and c-kit and analyzed by flow cytometry. In a
fourth experiment, spleen cells from untreated 4get    mice
and 4get   IL-5 Tgn    mice were compared. GFP c-
kitlowIgE CD3 SSChigh spleen cells were classified as eosino-
phils; GFP c-kit IgE CD3 SSCintermediate spleen cells were
classified as basophils, and GFP c-kit IgE CD3 SSCintermediate
spleen cells were classified as mast cells. (A) Gating strategies.
(B) Numbers of GFP  cells of each non–T cell type. Separate
groups of control (saline-treated) mice were used for each ex-
periment. Mice differed in age and sex between experiments,
explaining modest differences among control groups, but were
age and sex matched within each experiment. (C) Median
fluorescence intensity of basophil, mast cell, and eosinophil
GFP staining in untreated and IL-3–treated mice.Khodoun et al. 863
were performed to evaluate the importance of each possible
cell type, using GaMD, GaKLH, or anti-IgE mAb to elicit
an IL-4 response, the IVCCA to measure in vivo IL-4 pro-
duction, anti-CD4 mAb to block the response of conven-
tional CD4  T cells (42), CD1 deficiency to block NKT
development (43), anti-IgE mAb to desensitize the basophil
IL-4 response to antigen challenge (44), c-kit deficiency to
block mast cell development and survival (45), and anti-
Ly6G/C mAb to deplete eosinophils (46). Although treat-
ment with anti-CD4 mAb 1 d after GaMD immunization
inhibited the IL-4 response to challenge with goat serum by
 99%, treatment of GaMD-primed mice with anti-CD4
mAb 1 d before goat serum challenge had little effect on the
initial (4 h) IL-4 response (Fig. 5 A). Thus, conventional
CD4  T cells appear to be absolutely required for priming
for the secondary IL-4 response, but not for the effector
phase of that response. Treatment with anti-IgE mAb 1 d
before challenge had a considerably greater inhibitory effect
on the IL-4 response made during the first 4 h after antigen
challenge than did pretreatment with anti-CD4 mAb (Fig. 5
B), suggesting that basophils and/or mast cells are a more
important source of the initial secondary IL-4 response than
conventional CD4  T cells. Consistent with this, the initial
IL-4 response to goat serum challenge in GaMD-primed
mice was reduced by  90% in mice that lacked Fc RI (Fig.
5 C). Pretreatment with both anti-IgE and anti-CD4 mAbs
completely abolished the initial secondary IL-4 response to
antigen challenge (Fig. 5 B), demonstrating that CD4  T
cells and IgE-expressing cells (basophils/mast cells) together
account for the entire response.
Although both CD4  T cells and Fc RI  cells contribute
to the secondary IL-4 response, kinetics of IL-4 production
by these cell types differ. Anti-IgE mAb, but not anti-CD4
mAb, inhibited the initial (2 h) IL-4 response, as was shown
in our earlier experiment, whereas anti-CD4 mAb, but not
anti-IgE mAb, blocked responses made  6 h after antigen
challenge (Fig. 5, D and E). Thus, although Fc RI  cells are
responsible for the initial secondary IL-4 response, IL-4 pro-
duction by these cells is short lived and rapidly replaced by
IL-4 production by memory CD4  T cells.
Figure 5. IL-4 secretion during the secondary response to goat serum in GaMD-primed mice. (A) BALB/c mice were immunized with GaMD and
injected i.v. 1 or 13 d after GaMD immunization with 1 mg anti-CD4 mAb or control mAb. Mice were challenged with GaKLH on day 14 and injected
at the time of challenge with B IL-4 and bled 4 h later. (B) BALB/c mice were primed with GaMD. Some were injected 13 d later with anti-CD4 mAb
and/or i.p. with 200  g anti-IgE mAb or control mAbs. Mice were left unchallenged or were injected i.p. on day 14 with GaMD or GaKLH and were
injected at the same time with B IL-4 and bled 4 h later. (C) Wild-type or Fc RI-deficient mice on a BALB/c background were primed with GaMD.
Some mice were injected 13 d later with anti-CD4 mAb or control mAb. Mice were challenged on day 14 with saline or GaKLH and injected with
B IL-4 at the time of challenge and bled 2 h later. (D) BALB/c mice were primed with GaMD. Some were injected 13 d later with 200  g anti-IgE
mAb or control mAb. One group was challenged with saline (“time 0” group); all others were challenged with GaKLH on day 14. Saline-challenged
mice were injected with B IL-4 at the time of challenge; GaKLH-challenged mice were injected with B IL-4 at the time of challenge or 2, 4, 48, or 96 h
later. All mice were bled 2 h after B IL-4 injection. (E) An experiment identical to that described in D was performed, with the exception that some
mice were injected on day 13 with 1 mg anti-CD4 mAb or isotype-matched mAb instead of anti-IgE mAb and that an additional group of mice was as-
sayed for IL-4 production 24 h after challenge. (F) Unprimed BALB/c mice were injected on day 0 with anti-CD4 mAb or control mAb. Mice were in-
jected with B IL-4   10  g anti-CD3 mAb and bled 2 h later. (G) Wild-type or CD1-deficient mice were immunized with GaMD. All mice were in-
jected with 100  g anti-IgE mAb 13 d later, challenged with GaKLH, injected with B IL-4 on day 14, and bled 6 h later. (H) BALB/c mice (5/group)
were immunized i.p. with 1 mg OVA/d on days 0–5, treated with saline, 1 mg GK1.5, 200  g EM-95, or 1 mg GK1.5   200  g EM-95 i.p. on day 13,
and challenged i.p. with saline or 2 mg OVA on day 14. All mice were injected with B IL-4 mAb at the time of challenge and bled 4 h later. Similar re-
sults were observed when mice were immunized twice i.p. with OVA/alum and challenged i.p. with soluble OVA (not depicted).Secondary IL-4 Response 864
Figure 6. In vivo cytokine responses to anti-IgE mAb. (A) BALB/c mice were primed with GaMD and challenged 14 d later with anti-IgE mAb. IL-2,
IL-3, IL-4, IL-5, IL-13, TNF, and IFN-  production during the subsequent 24 h were measured by IVCCA. Quantities of different cytokines detected
are not comparable; the assays for IL-3 and IL-5 are less efficient than the other assays. (B) BALB/c mice were left unprimed or were primed with
GaMD, GaKLH, allo-anti-IgDa mAbs (H a/1 and FF1-4D5), or GaKLH   H a/1 and FF1-4D5. All mice were challenged 14 d later with anti-IgE mAb
and injected at the same time with B IL-4 and bled 4 h after challenge. (C) Wild-type and Fc RI-deficient mice on a BALB/c background were primed
with GaMD. Mice were challenged 14 d later with 200  g anti-IgE mAb and injected with B IL-4 at the same time. Mice were bled 4 h later. (D)
Unprimed wild-type and IgE-deficient mice were challenged with anti-IgE mAb or were first injected with IgE and challenged with anti-IgE mAb 1 d
later. All mice were injected with B IL-4 at the time of challenge and bled 24 h later. (E) BALB/c mice were primed with    mAbs and challenged 14 d
later with anti-IgE mAb, anti-Fc RII/RIII mAb, or anti-IgE   anti-Fc RII/RIII mAb. All mice were injected with B IL-4 at the time of challenge
and bled 3 h later. (F) c-kit–deficient W/Wv mice or age-matched W/  mice were primed with GaMD and were left unchallenged or were challenged
with anti-IgE mAb 14 d later. All mice were injected with B IL-4 at the time of challenge and were bled 4 h later. (G) BALB/c mice were primed with
GaMD and challenged 14 d later with saline or 1–100  g anti-IgE mAb. All mice were injected with B IL-4 at the time of challenge and bled 4 h later.
Serum MMCP1 levels were determined by ELISA. (H) BALB/c mice were primed with GaMD. (top) Mice were challenged 14 d later with anti-IgEKhodoun et al. 865
Because NKT cells, as well as conventional T cells, can
express CD4 and can rapidly produce IL-4 in response to
appropriate stimulation (5), we evaluated whether NKT
cells contribute to the secondary IL-4 response in GaMD-
primed mice. Because the in vivo IL-4 response to anti-
CD3 mAb is made by NKT cells and anti-CD4 mAb
blocks the conventional T cell response to antigen chal-
lenge, we studied whether anti-CD4 mAb would inhibit
the IL-4 response to anti-CD3 mAb. No inhibition was
detected (Fig. 5 F). Because CD1-deficient mice have few
NKT cells (43), we compared IL-4 responses of GaMD-
primed wild-type versus CD1-deficient mice to goat serum
challenge when the basophil/mast cell response was blocked
by pretreatment with anti-IgE mAb. Similar secondary
IgE-independent IL-4 responses were made by both mouse
strains (Fig. 5 G). Thus, conventional CD4  T cells appear
to be more important that NKT cells as a source of the sec-
ondary IL-4 response to a TD antigen.
Because GaMD is an unusually potent T cell–dependent
antigen, it was possible that our observations with GaMD-
immunized mice might not extend to mice immunized
with more conventional antigens. To evaluate this possibil-
ity, we immunized mice with six consecutive daily i.p. in-
jections of OVA and studied their IL-4 responses to OVA
challenge 14 d after the initial immunization (Fig. 5 H). Al-
though the secondary IL-4 response was much smaller in
OVA-primed and challenged mice than in mice primed
and challenged with GaMD, the secondary responses in the
GaMD and OVA systems were qualitatively similar; baso-
phils and CD4  T cells contributed substantially to IL-4
production and accounted for nearly all of the IL-4 pro-
duced in both systems.
Characterization of the IL-4 Response to Fc RI Cross-linking
in GaMD-primed Mice.  To further define the roles of
Fc RI  cells in the secondary IL-4 response, studies were
performed in which anti-IgE mAb was used to elicit IL-4 se-
cretion. Challenge of GaMD-primed mice with anti-IgE
mAb induced production of IL-2, IL-3, IL-4, IL-5, IL-13,
and TNF, but not IFN-  (Fig. 6 A). IL-4 and IL-13 re-
sponses appeared particularly large, with levels increasing
 1,000-fold over background. IL-4 responses made by anti-
IgE mAb-challenged unprimed or GaKLH-primed mice
were less, by a factor of 10–50, than responses made after
priming with anti-IgD antibody (Fig. 6 B). No IL-4 re-
sponses were made by anti-IgE, mAb-challenged, Fc RI -
deficient mice (Fig. 6 C), or IgE-deficient mice, unless the
latter mice were first injected with IgE (Fig. 6 D). Although
basophils produce IL-4 in vitro in response to immobilized
IgG (44), in vivo treatment with 24G2, a mAb to Fc RII
and Fc RIII, neither induced IL-4 production nor inhibited
anti-IgE mAb-induced IL-4 production (Fig. 6 E).
Although the Il4 gene is accessible in mast cells (Fig. 4 C)
and intestinal mastocytosis develops in GaMD-treated mice
(unpublished data), GaMD-primed mast cell–deficient
W/Wv mice and mast cell–sufficient mice made similar IL-4
responses to anti-IgE mAb challenge (Fig. 6 F). Dose–
response studies with anti-IgE mAb also dissociated mast
cells from the IL-4 response to anti-IgE mAb (Fig. 6 G).
The IL-4 response to anti-IgE mAb was barely evident in
mice treated with 2  g of anti-IgE mAb, but nearly full-
blown in mice injected with 4  g of this mAb. In contrast,
mast cell degranulation, as demonstrated by an increased
level of MMCP1, did not develop until mice received 8  g
of anti-IgE mAb and this response increased further as the
dose of anti-IgE mAb was raised. Together, these observa-
tions suggest that basophils contribute more than mast cells
to the anti-IgE mAb-induced mast cell response and indi-
cate that less Fc RI cross-linking is required to induce baso-
phil IL-4 secretion than to induce mast cell degranulation.
Kinetic studies indicated that the IL-4 response to anti-
IgE mAb begins rapidly and is short-lived (Fig. 6 H). In-
creased IL-4 production was observed 1 h after anti-IgE
mAb injection and reached a high level by 2 h, but was
complete by 4 h. Treatment of mice with as little as 2  g
anti-IgE mAb blocked the IL-4 response to 100  g of anti-
IgE mAb administered 12–24 h later (Fig. 6 I). In contrast,
treatment with anti-CD4 mAb 2 d before challenge with
anti-IgE mAb left most of the IL-4 response intact (Fig. 6 J).
Together with the data shown in Fig. 5, these observations
demonstrate that cross-linking of basophil Fc RI is responsi-
ble for the initial, large, IL-4 response produced by GaMD-
primed mice upon challenge with the relevant antigen, but
that this response terminates quickly and is replaced by a
more persistent response made by memory CD4  T cells.
Eosinophils Are Not Required for the Secondary IL-4 Re-
sponse in GaMD-primed Mice.  Eosinophils are the largest
GFP  cell population in the spleens of 4get mice (Figs. 2
and 3) and increase in number in GaMD-immunized mice
(Fig. 3 B). Although mouse eosinophils lack Fc RI (47),
their expression of Fc RIII (48) provides a potential mech-
anism for activation by IgG-containing immune com-
plexes. Although the nearly complete inhibition of the sec-
ondary IL-4 response to antigen challenge by anti-CD4
and anti-IgE mAbs (Fig. 5 B) suggested that eosinophils are
not involved in this response, our observation that eosino-
phils may express a small amount of CD4 (Fig. 2 C) raised
the possibility that anti-CD4 mAb might inhibit the sec-
ondary IL-4 response in part through an affect on eosino-
mAb; injected with B IL-4 2 h, 1 h and 45 min, 1 h and 30 min, or 1 h before challenge or at the time of challenge; and bled 2 h after B IL-4 injection.
(bottom) Mice were challenged with saline or anti-IgE mAb 14 d after priming. Challenged mice were injected with B IL-4 at the time of challenge or
4 or 8 h later. Mice were bled 4 h after B IL-4 injection. (I) BALB/c mice were primed with GaMD and challenged 14 d later. Some were challenged
with 2  g anti-IgE mAb and assayed for IL-4 production during the subsequent 4 h. Some mice were initially challenged with 2  g or 100  g anti-IgE
mAb 12 or 24 h before a second challenge with an additional 100  g anti-IgE mAb. All mice were injected with 10  g B IL-4 at the time of the final
challenge and bled 4 h later. (J) BALB/c mice were primed with GaMD. Some were injected with anti-CD4 mAb or a control mAb 12 d later. Mice
were left unchallenged or were challenged with anti-IgE mAb on day 14 and were simultaneously injected with B IL-4 and bled 4 h later. Treatment
with anti-CD4 mAb at the time of GaMD priming almost totally blocked the anti-IgE mAb-induced IL-4 response (not depicted).Secondary IL-4 Response 866
phils. To directly determine whether eosinophils make a
large contribution to the secondary IL-4 response, GaMD-
primed mice were treated with a cytotoxic anti-Ly6G/C
mAb that eliminates most neutrophils and eosinophils (Fig.
7, A and B). This treatment had no effect on the secondary
IL-4 response to antigen challenge, whether measured at
0–4, 4–8, or 24–28 h (Fig. 7 C). Anti-Ly6G/C mAb treat-
ment also had no significant effect on the secondary IL-4
response when the CD4  T cell and basophil components
of this response were blocked (Fig. 7 D). Thus, eosinophils
do not appear to contribute substantially to this response.
Discussion
Once our initial studies established that the secondary IL-4
response to a TD antigen is much larger and faster than
Figure 7. Eosinophil deple-
tion does not inhibit the second-
ary IL-4 response. BALB/c mice
were primed with GaMD and
injected 13 d later with 1 mg
anti-Ly6G/C or control mAb.
Some mice were killed on day 14
and their spleen cells were
counted and stained for CD3 and
CCR3. (A) Gating strategy. (B)
Number of SSChighCCR3 CD3 
cells/spleen. (C) Additional mice
were left unchallenged or were
challenged with GaKLH on day
14, injected with 10  g B IL-4
at the time of antigen challenge
or 4 or 24 h later and bled 4 h af-
ter B IL-4 injection. (D) Addi-
tional mice were treated with
saline, anti-CD4 and anti-IgE
mAbs, or anti-CD4, anti-IgE,
and anti-Ly6C/G mAbs on day
13. Mice were challenged with
GaKLH on day 14 or were left
unchallenged. IL-4 produced
0–4 h, 4–8 h, and 24–28 h after
challenge was determined. ND,
not determined.Khodoun et al. 867
the primary IL-4 response to the same antigen, experiments
were performed to identify the cell types that participate in
the secondary response and to characterize their secretion of
IL-4. Studies with 4get mice, in which cells with an accessi-
ble Il4 gene express GFP, identified memory CD4  T cells,
NKT cells, basophils, mast cells, and eosinophils in spleen as
cells that might rapidly produce IL-4 if appropriately stimu-
lated. The IVCCA was used to identify which of these cell
types contribute substantially to IL-4 production during the
secondary response. GaMD was used to prime for the sec-
ondary IL-4 response in these experiments because it rapidly
induces a large Th2 response that stimulates goat IgG-spe-
cific IgE production, mast cells, basophils, and goat IgG-
specific memory B and T cells (18, 49, 50).
Studies that used goat serum to elicit the secondary IL-4
response in GaMD-primed mice and the IVCCA to mea-
sure this response revealed that CD4  T cells are required
to prime for the response, whereas both conventional
CD4  T cells and Fc RI  basophils are important sources
of IL-4. The importance of basophils in an in vivo IL-4 re-
sponse and the requirement for CD4  T cells for genera-
tion of the basophil response have also been established in
studies in which Th2 cytokine production was induced by
infecting mice with the intestinal nematode parasite N. bra-
siliensis (reference 14; unpublished data).
Although both CD4  T cells and basophils were impor-
tant sources of the secondary IL-4 response in our studies,
IL-4 secretion by these cell types differed kinetically.
Fc RI  cells secreted maximal amounts of IL-4 within 2–4 h
of antigen challenge, after which time they secreted little
IL-4. In contrast, induction of maximal IL-4 secretion by
conventional CD4  T cells was slightly slower than induc-
tion of maximal IL-4 secretion by Fc RI  cells, albeit
much faster than induction of IL-4 secretion by naive
CD4  T cells during a primary immune response. Al-
though NKT cells can rapidly produce large quantities of
IL-4, they did not appear to participate to a great extent in
the secondary IL-4 response to goat serum, most likely be-
cause they respond to glycolipid antigens presented by
CD1 (35), whereas processing of goat IgG produces pep-
tides that are presented by MHC class II antigens.
Studies in which anti-IgE mAb was used instead of goat
serum to induce IL-4 secretion in GaMD-primed mice
confirmed the rapid induction and short duration of IL-4
secretion by Fc RI  cells and revealed that most of these
cells are basophils rather than mast cells (the IL-4 response
was not decreased in W/Wv mice). However, we cannot
rule out the possibility that mast cells produce a small per-
centage of the secondary IL-4 response.
These experiments also revealed quantitative differences
in the extent of Fc RI cross-linking required to induce ba-
sophil IL-4 secretion, as opposed to induction of mast cell
degranulation. Stimulation of basophil IL-4 secretion was
considerably more sensitive than induction of mast cell de-
granulation and may have been an all-or-nothing phenom-
enon because cells triggered with a small quantity of anti-
IgE mAb failed to secrete more IL-4 if restimulated within
24 h with a much larger amount of anti-IgE mAb. In con-
trast, the amount of mast cell degranulation, as measured by
serum levels of MMCP1, increased more gradually as larger
quantities of anti-IgE mAb were injected.
Together, our results suggest that three cell types, naive
CD4  T cells, basophils, and memory CD4  T cells con-
tribute substantially to IL-4 secretion during in vivo re-
sponses to TD antigens but contribute to this response in
different ways. Naive T cells require considerable time to
initiate IL-4 production during a primary immune response
to a TD antigen, most likely because their Il4 genes are ini-
tially inaccessible. The relatively small quantities of IL-4
that these cells secrete for several days once they become
activated should allow autocrine and paracrine delivery of
the IL-4 that drives Th2 cell differentiation and B cell iso-
type switching to IgE. In contrast, the rapid, easily trig-
gered, short-lived production of much larger quantities of
IL-4 (and additional cytokines) by basophils appears well
adapted to the activation of nonimmune cells, including
vascular endothelium, smooth muscle, and mucosal epithe-
lial cells, which modify their function to promote the ex-
pulsion of enteric nematode parasites when stimulated with
large amounts of IL-4 (1, 51).
Because in vivo secretion of massive amounts of IL-4 by
basophils appears to be predominantly or entirely dependent
on IgE-mediated Fc RI cross-linking and antigen-specific
IgE would not be available for several days after immuniza-
tion or infection, massive release of IL-4 by basophils might
serve as a specialized mechanism that promotes resistance to
reinfection with nematode parasites. In this regard, the
greater sensitivity of basophils to Fc RI cross-linking, as
compared with mast cells, might cause basophil IL-4 secre-
tion to precede mast cell degranulation during infection with
enteric worms. This difference in sensitivity may promote
host immunity because preexposure to IL-4 greatly sensitizes
nonbone marrow–derived cells, such as intestinal cells, to
mediators released by mast cells that promote rapid expulsion
of parasites such as Trichinella spiralis (52, 53). Indeed, T. spi-
ralis expulsion requires mast cells, IL-4, or IL-13, and non-
bone marrow–derived cells that are IL-4/IL-13 responsive
(53). However, it should be noted that others have shown
that basophils can be stimulated by CD4  T cells to secrete
relatively small amounts of IL-4 even in the absence of Ig
and B cells (14). Thus, basophils may be able to contribute to
IL-4–mediated immunity and inflammation through two
distinct mechanisms: an IgE-independent mechanism that
induces persistent production of small amounts of IL-4 and
an IgE-dependent mechanism that rapidly induces the secre-
tion of massive amounts of this cytokine.
Conventional CD4  T cells that have differentiated into
IL-4–producing memory cells share characteristics with
both naive CD4  T cells and basophils. Like basophils,
they rapidly produce large amounts of IL-4 when appropri-
ately stimulated; indeed, the short delay in IL-4 production
by these cells probably reflects the time required for antigen
to be bound and processed by APCs. Like naive conven-
tional CD4  T cells, memory T cells, once activated, pro-
duce IL-4 for a long time. Thus, IL-4–secreting memory
CD4  T cells may take up where Fc RI-activated baso-Secondary IL-4 Response 868
phils leave off in a secondary immune response to sustain
IL-4 effects on nonbone marrow–derived cells and provide
a relatively stable source of IL-4 that should promote addi-
tional isotype switching and Th2 differentiation.
Our observations by no means indicate that the other
GFP  cells in 4get mice, NKT cells, mast cells and eosino-
phils, are not sources of IL-4 in vivo. NKT cells produce
large amounts of IL-4 in mice injected with anti-CD3
mAb or  -gal-cer and, like basophils, secrete IL-4 for only
a few hours (54). The adaptive significance of this response,
which is accompanied by massive IFN-  production, is
uncertain.
Although eosinophils are the largest population of con-
stitutively GFP  spleen cells in 4get mice, depletion of this
population had no detectable effect on IL-4 responses in our
model. Furthermore, in vivo IL-4 production, as detected
by IVCCA, is only modestly increased in IL-5 transgenic
mice, which have greatly increased numbers of eosinophils
(55), and basal IL-4 levels are normal in IL-5–deficient
mice, which have relatively few eosinophils (reference 56;
unpublished data). These observations indicate that eosino-
phils, like other cell types that have an accessible Il4 gene,
must be appropriately activated to secrete IL-4. To date,
only contact with activated CD4  T cells has been shown
to provide a physiological stimulus that induces eosinophils
to secrete IL-4 (15). Thus, eosinophils may contribute little
to IL-4 production by themselves, but may amplify IL-4
responses made by CD4  T cells.
Even less can be said about the possible contributions of
mast cells to secondary in vivo IL-4 responses. Although
treatment with exogenous IL-3 stimulates the appearance
of GFP  spleen cells that are probably mast cells, it is un-
known whether the Il4 gene is in an accessible state in the
vascular mast cells that are present in unstimulated mice or
in mucosal mast cells that increase in response to GaMD
immunization and worm infection. It is also not known
whether secretion of IL-4 by mouse mast cells, if it occurs,
is regulated similarly to mast cell degranulation. These is-
sues are important to address because mast cells are located
at sites where IL-4 secretion could have important effects
on vascular permeability and parasite expulsion.
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